Skip to main content

Table 3 Overall response rate of included studies

From: Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

 

Number

Rate

95%CI

I2%

ORR

260/1129

0.16

0.06–0.31

96.39

DCR

544/1129

0.5

0.35–0.65

95.57

CR

41/1129

0.01

0.00–0.04

82.95

PR

219/1129

0.14

0.05–0.26

95.20

SD

284/1129

0.27

0.22–0.32

66.95

PD

513/1129

0.44

0.30–0.58

95.09

  1. ORR objective response rate, DCR disease control rate, CR complete response rate, PR partial response rate, SD stable disease rate, PD progression disease rate (PD)
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us